156 related articles for article (PubMed ID: 30952881)
1. Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-β oligomers.
Elfgen A; Hupert M; Bochinsky K; Tusche M; González de San Román Martin E; Gering I; Sacchi S; Pollegioni L; Huesgen PF; Hartmann R; Santiago-Schübel B; Kutzsche J; Willbold D
Sci Rep; 2019 Apr; 9(1):5715. PubMed ID: 30952881
[TBL] [Abstract][Full Text] [Related]
2. Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2.
Schemmert S; Schartmann E; Honold D; Zafiu C; Ziehm T; Langen KJ; Shah NJ; Kutzsche J; Willuweit A; Willbold D
Neurobiol Dis; 2019 Apr; 124():36-45. PubMed ID: 30391539
[TBL] [Abstract][Full Text] [Related]
3. Oral absorption enhancement of the amyloid-β oligomer eliminating compound RD2 by conjugation with folic acid.
Elfgen A; Santiago-Schübel B; Hupert M; Schemmert S; Schartmann E; Tusche M; Gering I; Zafiu C; Kutzsche J
Eur J Pharm Sci; 2021 Jan; 156():105581. PubMed ID: 33035662
[TBL] [Abstract][Full Text] [Related]
4. Surprisingly high stability of the Aβ oligomer eliminating all-d-enantiomeric peptide D3 in media simulating the route of orally administered drugs.
Elfgen A; Santiago-Schübel B; Gremer L; Kutzsche J; Willbold D
Eur J Pharm Sci; 2017 Sep; 107():203-207. PubMed ID: 28711713
[TBL] [Abstract][Full Text] [Related]
5. The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology.
van Groen T; Schemmert S; Brener O; Gremer L; Ziehm T; Tusche M; Nagel-Steger L; Kadish I; Schartmann E; Elfgen A; Jürgens D; Willuweit A; Kutzsche J; Willbold D
Sci Rep; 2017 Nov; 7(1):16275. PubMed ID: 29176708
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Properties of a Novel D-Peptide Developed to be Therapeutically Active Against Toxic β-Amyloid Oligomers.
Leithold LH; Jiang N; Post J; Ziehm T; Schartmann E; Kutzsche J; Shah NJ; Breitkreutz J; Langen KJ; Willuweit A; Willbold D
Pharm Res; 2016 Feb; 33(2):328-36. PubMed ID: 26381279
[TBL] [Abstract][Full Text] [Related]
7. Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer's Disease.
Kutzsche J; Schemmert S; Tusche M; Neddens J; Rabl R; Jürgens D; Brener O; Willuweit A; Hutter-Paier B; Willbold D
Molecules; 2017 Oct; 22(10):. PubMed ID: 28994710
[TBL] [Abstract][Full Text] [Related]
8. Toward the Mode of Action of the Clinical Stage All-d-Enantiomeric Peptide RD2 on Aβ42 Aggregation.
Zhang T; Gering I; Kutzsche J; Nagel-Steger L; Willbold D
ACS Chem Neurosci; 2019 Dec; 10(12):4800-4809. PubMed ID: 31710458
[TBL] [Abstract][Full Text] [Related]
9. Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer's Mice with Full-blown Pathology.
Schemmert S; Schartmann E; Zafiu C; Kass B; Hartwig S; Lehr S; Bannach O; Langen KJ; Shah NJ; Kutzsche J; Willuweit A; Willbold D
Mol Neurobiol; 2019 Mar; 56(3):2211-2223. PubMed ID: 30003517
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of an UHPLC-ESI-QTOF-MS method for quantification of the highly hydrophilic amyloid-β oligomer eliminating all-D-enantiomeric peptide RD2 in mouse plasma.
Hupert M; Elfgen A; Schartmann E; Schemmert S; Buscher B; Kutzsche J; Willbold D; Santiago-Schübel B
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1073():123-129. PubMed ID: 29248770
[TBL] [Abstract][Full Text] [Related]
11. Do We Need Anti-Prion Compounds to Treat Alzheimer's Disease?
Willbold D; Kutzsche J
Molecules; 2019 Jun; 24(12):. PubMed ID: 31208037
[TBL] [Abstract][Full Text] [Related]
12. Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of d-Enantiomeric Peptides Designed to Eliminate Cytotoxic Aβ Species.
Ziehm T; Brener O; van Groen T; Kadish I; Frenzel D; Tusche M; Kutzsche J; Reiß K; Gremer L; Nagel-Steger L; Willbold D
ACS Chem Neurosci; 2016 Aug; 7(8):1088-96. PubMed ID: 27240424
[TBL] [Abstract][Full Text] [Related]
13. In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer's Disease.
Schartmann E; Schemmert S; Niemietz N; Honold D; Ziehm T; Tusche M; Elfgen A; Gering I; Brener O; Shah NJ; Langen KJ; Kutzsche J; Willbold D; Willuweit A
J Alzheimers Dis; 2018; 64(3):859-873. PubMed ID: 29966196
[TBL] [Abstract][Full Text] [Related]
14. Blood-brain barrier penetration of an Aβ-targeted, arginine-rich, d-enantiomeric peptide.
Jiang N; Frenzel D; Schartmann E; van Groen T; Kadish I; Shah NJ; Langen KJ; Willbold D; Willuweit A
Biochim Biophys Acta; 2016 Nov; 1858(11):2717-2724. PubMed ID: 27423267
[TBL] [Abstract][Full Text] [Related]
15. Optimization of d-Peptides for Aβ Monomer Binding Specificity Enhances Their Potential to Eliminate Toxic Aβ Oligomers.
Klein AN; Ziehm T; van Groen T; Kadish I; Elfgen A; Tusche M; Thomaier M; Reiss K; Brener O; Gremer L; Kutzsche J; Willbold D
ACS Chem Neurosci; 2017 Sep; 8(9):1889-1900. PubMed ID: 28581708
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic properties of tandem d-peptides designed for treatment of Alzheimer's disease.
Leithold LH; Jiang N; Post J; Niemietz N; Schartmann E; Ziehm T; Kutzsche J; Shah NJ; Breitkreutz J; Langen KJ; Willuweit A; Willbold D
Eur J Pharm Sci; 2016 Jun; 89():31-8. PubMed ID: 27086111
[TBL] [Abstract][Full Text] [Related]
17. Oral treatment with the all-d-peptide RD2 enhances cognition in aged beagle dogs - A model of sporadic Alzheimer's disease.
Kutzsche J; Schemmert S; Bujnicki T; Zafiu C; Halbgebauer S; Kraemer-Schulien V; Pils M; Blömeke L; Post J; Kulawik A; Jürgens D; Rossberg WM; Hümpel M; Bannach O; Otto M; Araujo JA; Willuweit A; Willbold D
Heliyon; 2023 Aug; 9(8):e18443. PubMed ID: 37609390
[TBL] [Abstract][Full Text] [Related]
18. Optimization of the All-D Peptide D3 for Aβ Oligomer Elimination.
Klein AN; Ziehm T; Tusche M; Buitenhuis J; Bartnik D; Boeddrich A; Wiglenda T; Wanker E; Funke SA; Brener O; Gremer L; Kutzsche J; Willbold D
PLoS One; 2016; 11(4):e0153035. PubMed ID: 27105346
[TBL] [Abstract][Full Text] [Related]
19. How do membranes initiate Alzheimer's Disease? Formation of toxic amyloid fibrils by the amyloid β-protein on ganglioside clusters.
Matsuzaki K
Acc Chem Res; 2014 Aug; 47(8):2397-404. PubMed ID: 25029558
[TBL] [Abstract][Full Text] [Related]
20. Role of Hydrophobicity and Charge of Amyloid-Beta Oligomer Eliminating d-Peptides in the Interaction with Amyloid-Beta Monomers.
Ziehm T; Buell AK; Willbold D
ACS Chem Neurosci; 2018 Nov; 9(11):2679-2688. PubMed ID: 29893543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
